Jamshed Shazia, Bhagavathula Akshaya Srikanth, Zeeshan Qadar Sheikh Muhammad, Alauddin Umaira, Shamim Sana, Hasan Sohail
International Islamic University Malaysia, Kuala Lumpur, Malaysia.
University of Gondar, Ethiopia.
Hosp Pharm. 2020 Oct;55(5):292-305. doi: 10.1177/0018578719893378. Epub 2019 Dec 18.
Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder that results from regurgitation of acid from the stomach into the esophagus. Treatment available for GERD includes lifestyle changes, antacids, histamine-2 receptor antagonists (HRAs), proton pump inhibitors (PPIs), and anti-reflux surgery. The aim of this review is to assess the cost-effectiveness of the use of PPIs in the long-term management of patients with GERD. We searched in PubMed to identify related original articles with close consideration based on inclusion and exclusion criteria to choose the best studies for this narrative review. The first section compares the cost-effectiveness of PPIs with HRAs in long-term heartburn management. The other sections shall only discuss the cost-effectiveness of PPIs in 5 different strategies, namely, continuous (step-up, step-down, and maintenance), on-demand, and intermittent therapies. Of 55 articles published, 10 studies published from 2000 to 2015 were included. Overall, PPIs are more effective in relieving heartburn in comparison with ranitidine. The use of PPIs in managing heartburn in long-term consumption of nonsteroidal anti-inflammatory drug (NSAID) has higher cost compared with HRA. However, if the decision-maker is willing to pay more than US$174 788.60 per extra quality-adjusted life year (QALY), then the optimal strategy is traditional NSAID (tNSAID) and PPIs. The probability of being cost-effective was also highest for NSAID and PPI co-therapy users. On-demand PPI treatment strategy showed dominant with an incremental cost-effectiveness ratio of US$2197 per QALY gained and was most effective and cost saving compared with all the other treatments. The average cost-effectiveness ratio was lower for rabeprazole therapy than for ranitidine therapy. Our review revealed that long-term treatment with PPIs is effective but costly. To achieve long-term cost-effective approach, we recommend on-demand approach to treat heartburn symptoms, but if the symptoms persist, treatment with continuous step-down therapy should be applied.
胃食管反流病(GERD)是一种常见的胃肠道疾病,由胃酸从胃反流至食管引起。GERD的治疗方法包括生活方式改变、抗酸剂、组胺-2受体拮抗剂(HRAs)、质子泵抑制剂(PPIs)和抗反流手术。本综述的目的是评估使用PPIs对GERD患者进行长期管理的成本效益。我们在PubMed中进行检索,根据纳入和排除标准仔细筛选相关原始文章,以选择最适合本叙述性综述的研究。第一部分比较了PPIs与HRAs在长期治疗烧心方面的成本效益。其他部分将仅讨论PPIs在5种不同策略中的成本效益,即持续(逐步升级、逐步降级和维持)、按需和间歇治疗。在发表的55篇文章中,纳入了2000年至2015年发表的10项研究。总体而言,与雷尼替丁相比,PPIs在缓解烧心方面更有效。与HRA相比,长期服用非甾体抗炎药(NSAID)时使用PPIs治疗烧心的成本更高。然而,如果决策者愿意为每增加一个质量调整生命年(QALY)支付超过174788.60美元,那么最佳策略是传统NSAID(tNSAID)和PPIs。NSAID和PPI联合治疗使用者的成本效益概率也最高。按需PPI治疗策略显示出优势,每获得一个QALY的增量成本效益比为2197美元,与所有其他治疗相比最有效且节省成本。雷贝拉唑治疗的平均成本效益比低于雷尼替丁治疗。我们的综述表明,PPIs长期治疗有效但成本高昂。为了实现长期成本效益高的方法,我们建议采用按需方法治疗烧心症状,但如果症状持续,应采用持续逐步降级疗法进行治疗。